EDMONTON, Aug. 5 /CNW/ - Valens Pharma Ltd. (Valens, formerly known as
"CardioMetabolics Inc."), today announced that the Company has suspended work
on its DCA i.v program, a proprietary intravenous formulation of
dichloroacetate pending further review by its Scientific Advisory Board. Based
on the analysis of the voluntary Phase II "Mini-Metrxics" clinical trial by
the Company's Scientific Advisory Board to date, it is clear that Valens does
not have sufficient evidence to quickly move into its planned Phase III
METRxICS Trial as had been anticipated. As previously announced, while data
from the Phase II trial met certain biochemical endpoints, the anticipated
clinical signals of a reduction in time spent in the intensive care unit
(ICU), a reduction in ventilator times and a reduction in hospital times were
not present. While there were no deaths during the actual trial in this high
risk geriatric population, there were more adverse events in the group that
received DCA compared to the control group. Requests for further information
may be directed to the Company.
